Boehringer Ingelheim has introduced LENZELTA®, a new vaccine designed to significantly reduce the incidence and severity of clinical mastitis in dairy cows and heifers, marking a major advancement in herd health management.
The vaccine targets two key mastitis-causing pathogens—Staphylococcus aureus and Escherichia coli—and offers both the earliest onset of immunity and long-lasting protection of up to six months, covering the most vulnerable period around calving. (GlobeNewswire)
Administered in two doses during the dry-off period, LENZELTA® is designed for easy integration into existing herd health routines, enabling proactive disease prevention.
Mastitis remains one of the most widespread and economically damaging diseases in dairy farming, impacting udder health, reducing milk yield and quality, and contributing to significant financial losses for producers.
The vaccine uses an oil-free adjuvant and is available in multiple vial sizes, providing flexibility for veterinarians. With its launch across several European Union countries from April 2026, Boehringer Ingelheim aims to strengthen its mastitis prevention portfolio and support farmers in improving herd productivity, animal welfare, and overall farm profitability.
Source: Dairynews7x7 14 April, 2026 Read full story here
#DairyHealth #MastitisControl #AnimalHealth #DairyInnovation #LivestockCare #MilkQuality #Dairynews7x7